Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: Thomas Kelly who wrote (740)	9/10/1999 1:43:00 PM
From: agent99	Respond to of 849

=DJ Matritech Up-3: Pres: Need To Test More Specimens Matritech has much work to complete before it can submit the first-of-its-kind breast cancer blood screen to the Food and Drug Administration, according to Corbet, Matritech's president. However, if additional supporting data is gathered, Matritech hopes to engage in clinical trials next year. "We need to test more specimens and optimize the research procedure." Corbet said. "There are a couple of ways to do that." Matritech could reduce the current procedure to a more user-friendly test so other clinical laboratories could use the screen or Matritech could offer the test through sophisticated commercial laboratories in a modified form of the current research, Corbet said. Matritech plans to consider both strategies. "Given that breast cancer is arguably the most visible disease in the U.S., and given the importance of this data, we are doing our best to expedite" the process, Corbet said. According to the American Cancer Society, women must currently rely on self-examination, clinical examination and mammography for diagnosis of breast cancer, which is the second most common cancer among women, the second leading cause of cancer death in all women, and the leading cause of cancer death in women ages 40 to 55. The American Cancer Society estimates there will be about 175,000 new cases of invasive breast cancer in the U.S. this year, and about 43,300 deaths from the disease. If it proves reliable, Matritech's screen would be the first blood test for breast cancer, according to Corbet. And since in its earliest stages breast cancer produces no otherwise detectable symptoms, it would be an especially useful weapon against the disease. (MORE) DOW JONES NEWS 09-10-99 01:41 PM